Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced a services agreement with Nanosoft Polymers to support the development of ONC010, the company’s lead nanoparticle-formulated PNKP inhibitor. The collaboration aims to strengthen the manufacturing and formulation foundation of ONC010 by establishing scalable polymer production processes, enhancing analytical methods, and supporting future GMP manufacturing readiness.
Under the agreement, Nanosoft will provide polymer process development, analytical characterization, formulation optimization, scale-up support, and technology transfer services for Onco’s proprietary PEO-PBCL polymer platform as the program advances through IND-enabling development and preparation for future clinical studies. This partnership is a critical step in preparing ONC010 for first-in-human clinical evaluation.
The work with Nanosoft will complement ongoing chemistry, manufacturing, and controls (CMC) activities with Dalton Pharma Services and preclinical development efforts at Nucro-Technics. By integrating these efforts, Onco-Innovations aims to ensure that ONC010 is built on a robust and scalable manufacturing process, which is essential for regulatory approval and eventual commercialization.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology that targets solid tumours, positioning it to address significant unmet needs in oncology.
The importance of this announcement lies in the advancement of ONC010, a novel therapeutic that targets solid tumours through PNKP inhibition. By engaging Nanosoft, Onco-Innovations is addressing key challenges in nanoparticle drug delivery, such as scalability and formulation consistency. This could accelerate the timeline to clinical trials and ultimately provide new treatment options for patients with solid tumours.
For investors and the industry, the partnership signals progress in Onco’s pipeline and a commitment to rigorous development standards. The successful scale-up and GMP readiness of ONC010 could enhance the company’s valuation and attract further partnership opportunities. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
As Onco-Innovations moves forward, the collaboration with Nanosoft represents a strategic investment in the technical foundation of its lead candidate. With multiple partners contributing to CMC and preclinical work, the company is building a comprehensive development framework that could de-risk the path to clinical evaluation. The full press release is available at https://ibn.fm/djEgt.
